查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
高藥理活性API市場規模，佔有率，趨勢分析:各類型，各合成，各製造廠商，各用途，各地區展望，競爭策略，至2030年的各市場區隔預測
市場調查報告書
商品編碼
1089969

高藥理活性API市場規模，佔有率，趨勢分析:各類型，各合成，各製造廠商，各用途，各地區展望，競爭策略，至2030年的各市場區隔預測

High Potency APIs Market Size, Share & Trends Analysis By Type, By Synthesis, By Manufacturers, By Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 223 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球高藥理活性API的市場規模，預計今後以6.9％的年複合成長率擴大，至2030年達到370億美元。腫瘤治療藥的需求擴大，抗體藥物複合體的採用增加，高藥理活性API相關大型製藥公司的關注高漲，高藥理活性API的製造方法的開發，精密醫療的關注高漲等，成為促進這個市場的主要原因。

本報告提供全球高藥理活性API市場相關調查，市場概要，以及各類型，各合成，各製造廠商，各用途，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長要素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • COVID-19高藥理活性API市場的影響

第5章 市場變數及預測

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 熱圖分析

第6章 全球高藥理活性API市場，各類型，2019年～2030年(100萬美元)

  • 簡介
  • 創新的高藥理活性API
  • 一般的高藥理活性API

第7章 全球高藥理活性API市場，各合成，2019年～2030年(100萬美元)

  • 簡介
  • 合成API
  • 生物科技API

第8章 全球高藥理活性API市場，各製造廠商，2019年～2030年(100萬美元)

  • 簡介
  • 專屬式廠商
  • 商人廠商

第9章 全球高藥理活性API市場，各用途，2019年～2030年(100萬美元)

  • 簡介
  • 腫瘤學
  • 荷爾蒙平衡的異常
  • 青光眼
  • 其他

第10章 全球高藥理活性API市場，各地區，2019年～2030年(100萬美元)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第11章 企業簡介

  • AbbVie
  • Albany Molecular Research Inc.
  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Carbogen Amcis
  • Cipla Inc.
  • Corden Pharma International
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Lonza
  • Merck & Co., Inc
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
簡介目錄
Product Code: PHAR2205

High Potency APIs Market is projected to be worth USD 37.0 billion by 2030.

According to SPER Market Research, High Potency APIs Market is estimated to reach USD 37.0 billion by 2030 with a CAGR of 6.9%. Expanding need for oncology medications, increasing adoption for antibody-drug conjugates, increased attention of prominent pharmaceutical companies on High Potency APIs, developments in High Potency APIs manufacturing methods, and growing focus on precision medicine are all driving this market forward.

Impact of COVID-19 on the High Potency APIs Market

High Potency APIs market was negatively impacted by the COVID-19 outbreak. COVID-19 significantly impacted this market supply chain. The economic scenario induced by the COVID-19 pandemic in 2020 has hindered the development of this market severely. As the share of enterprises outsourcing to countries with low-cost production technology grows at a rapid rate, companies are expected to benefit.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Type, By Synthesis, By Manufacturers, By Application
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered

AbbVie, Albany Molecular Research Inc., BASF SE, Bayer AG, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, Carbogen Amcis, Cipla Inc., CordenPharma International, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche, Lonza, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc.

Driver: Rising demand for cancer medications

Rising cancer medicine demand is expected to open up a wide range of prospects in the worldwide High Potency API market. High Potency APIs are highly effective pharmacologically active compounds that provide significant action and efficiency even at low dosages. Because of the increasing incidence and prevalence of cancer, there is an increase in need for more effective cancer therapies, such as High Potency APIs. To meet the rising demand, pharmaceutical companies such as Pfizer, Sanofi, F. Hoffmann-La Roche, and others are putting more effort into developing pipelines for innovative cancer therapies.

Restraint: Cross-contamination is a major concern

Cross-contamination is one of the most serious concerns connected with High Potency API production. Mounting emphasis on the pharmaceutical business to minimise costs and make biopharmaceuticals more affordable to users are important factors encouraging the industry to use as many effective and efficient multi-product and multi-purpose facilities as possible. High Potency APIs frequently demonstrate high cytotoxicity in addition to high potency, so measures to minimise cross-contamination are critical to a safe production process that ensures the wellness of staff, the surroundings, and the patient.

Opportunity: Opportunities for CMOs and CDMOs are expanding

A complete High Potency API production plant necessitates thorough planning, the use of risk mitigation and assessment techniques, and a process for determining which compounds are eligible for production in each facility. The manufacture of such chemicals is hazardous to employees and the environment. Pharmaceutical companies must also be able to safely produce, store, and transport a growing number of strong substances. This demonstrates that building an effective High Potency API production plan necessitates substantial time and investment. As a result, many sponsor firms choose to seek assistance from CMOs and CDMOs for the development, production, and distribution of High Potency APIs and their formulated medicinal products, as some of these organizations have the proper equipment.

Challenges: Processes must be designed correctly

Among the most important needs for High Potency API production process is process design. The majority of High Potency APIs must be manufactured in tiny clinical and commercial quantities. However, producing gram scale GMP APIs and payloads is difficult. Ensuring containment control while using flexible and tiny equipment, especially glass equipment, is a significant problem that necessitates a customised method for each process and unit operation. It is also critical to retain proper process designs at the developmental size to guarantee that the process suits the plant equipment and capacities when scaled up. Furthermore, there is confusion in the business regarding the types of High Potency APIs. Because of an insufficient data, the classification of new APIs is uncertain due to the use of proprietary systems by various pharmaceutical corporations. These problems can be avoided with proper process designs and containment controls, which most businesses lack. All of these reasons, taken together, are expected to pose a considerable challenge to High Potency API market participants.

Global High Potency APIs Market, By Type:

Based on the Type, Global High Potency APIs Market is segment as; Innovative High Potency APIs, Generic High Potency APIs.

Global High Potency APIs Market, By Synthesis:

Based on the Synthesis, Global High Potency APIs Market is segment as; Synthetic APIs (Synthetic APIs Market By Type), Biotech APIs (Biotech APIs Market By Type, Biotech APIs Market By Product, Vaccines, Recombinant Proteins).

Global High Potency APIs Market, By Manufacturer:

Based on the Manufacturer, Global High Potency APIs Market is segment as; Captive High Potency APIs Manufacturers, Merchant High Potency APIs Manufacturers (Merchant High Potency APIs Manufacturers Market By Type, Merchant High Potency APIs Manufacturers Market By Type of Synthesis, Synthetic APIs, Biosynthetic APIs).

Global High Potency APIs Market, By Application:

Based on the Application, Global High Potency APIs Market is segment as; Oncology, Hormonal Imbalance, Glaucoma, Other Therapeutic Applications.

Global High Potency APIs Market, By Region:

North America owns the prime share of this market; this is due to the increasing prevalence of cancer, also China is growing faster in the Asia-Pacific region.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the High Potency APIs Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global High Potency APIs Market, By Type, 2019-2030 (USD Million)

  • 6.1. Introduction
  • 6.2. Innovative High Potency APIs
  • 6.3. Generic High Potency APIs

7. Global High Potency APIs Market, By Synthesis, 2019-2030 (USD Million)

  • 7.1. Introduction
  • 7.2. Synthetic APIs
    • 7.2.1. Synthetic APIs Market, By Type
  • 7.3. Biotech APIs
    • 7.3.1 Biotech APIs Market, By Type
    • 7.3.2 Biotech APIs Market, By Product
    • 7.3.3 Vaccines
    • 7.3.4 Recombinant Proteins

8. Global High Potency APIs Market, By Manufacturer, 2019-2030 (USD Million)

  • 8.1. Introduction
  • 8.2. Captive High Potency APIs Manufacturers
  • 8.3. Merchant High Potency APIs Manufacturers
    • 8.3.1 Merchant High Potency APIs Manufacturers Market, By Type
    • 8.3.2 Merchant High Potency APIs Manufacturers Market, By Type of Synthesis
    • 8.3.3 Synthetic APIs
    • 8.3.4 Biosynthetic APIs

9. Global High Potency APIs Market, By Application, 2019-2030 (USD Million)

  • 9.1. Introduction
  • 9.2. Oncology
  • 9.3. Hormonal Imbalance
  • 9.4. Glaucoma
  • 9.5. Other Therapeutic Applications

10. Global High Potency APIs Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. AbbVie
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Albany Molecular Research Inc.
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. BASF SE
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Bayer AG
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Boehringer Ingelheim International GmbH.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Bristol-Myers Squibb Company
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Carbogen Amcis
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cipla Inc.
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Corden Pharma International
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Dr. Reddy's Laboratories Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Eli Lilly and Company
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. F. Hoffmann-La Roche
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Lonza
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Merck & Co., Inc.
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Novartis International AG
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Pfizer, Inc.
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Sanofi
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Sun Pharmaceutical Industries, Ltd.
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Teva Pharmaceutical Industries Ltd.
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Viatris Inc.
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments

10. Global High Potency APIs Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. AbbVie
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Albany Molecular Research Inc.
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. BASF SE
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Bayer AG
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Boehringer Ingelheim International GmbH.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Bristol-Myers Squibb Company
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Carbogen Amcis
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cipla Inc.
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Corden Pharma International
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Dr. Reddy's Laboratories Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Eli Lilly and Company
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. F. Hoffmann-La Roche
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Lonza
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Merck & Co., Inc.
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Novartis International AG
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Pfizer, Inc.
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Sanofi
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Sun Pharmaceutical Industries, Ltd.
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Teva Pharmaceutical Industries Ltd.
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Viatris Inc.
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments